Business Wire

Iceland’s #1 Dating App, Smitten, Raises $10M Series A From Makers Fund, Possible Ventures and More to Woo Gen Z-ers Globally With Its Fresh Approach to Dating

15.9.2022 14:01:00 EEST | Business Wire | Press release

Share

Dating app Smitten has raised a $10M Series A from Makers Fund, Possible Ventures, Wonder Invest and current shareholders ByFounders, ProFounders, Tennin, and Smitten's board member and Vivino founder Heini Zachariassen. Smitten, the most popular dating app in Iceland and the second most popular in Denmark, will use the financing to grow its team and to expand to new markets as they woo Gen Zers with their fresh, gamified approach to dating.

“My co-founder, Asgeir, and I share an intense interest in how people connect and communicate,” says David Simonarson, Smitten Co-Founder and CEO. “After years of creating social consumer apps, we fell in love with the online dating space and launched Smitten in 2020. We created personality-based games and fun interactive profiles to make it easy for strangers to form meaningful connections. Seeing how much our users love Smitten, we believe we can become the leading player in online dating for Generation Z.”

Smitten is founded by David Simonarson, CEO, and Asgeir Visir, Designer, and was released by the founders and its CTO, Magnus Olafsson. Smitten mixes games, entertainment, and flirting to jumpstart conversations and help users engage more seamlessly. Smitten's fun and creative approach to dating has struck a chord with Gen Zers, proven by the app’s more than 200 million swipes to date and whopping 30%+ stickiness rate. Most dating apps leave people to convert a match into a conversation with awkward starts that lead nowhere. Smitten makes getting into a conversation as easy as swiping through use of games, interactive profiles and icebreakers. Smitten gets users into fun, quality conversations regardless of their conversation skills, and has found that more than 60% of Smitten matches result in a post-match interaction vs 11% on industry-leading app, Tinder*.

The key to Smitten’s post-match interactions are mini-games people can play on each other’s profiles. “Our questionnaire game, Guessary, allows you to get to know the other person you are viewing by guessing how they answered a series of Yes-and-No questions,” explained Asgeir Visir, Smitten Co-Founder and Designer. “You could be answering questions like ‘Have they ever been arrested?’ or ‘Do they like pineapple on their pizza?’ and you would get immediate feedback if you answered correctly or not. Another fun game, Lie Detector, is inspired by the age-old social game Two Truths and Lie, where people add three statements about themselves to their profile, and you have one chance to spot the lie. These games are designed for users to get to know the person they are viewing before deciding if they want to like them or not. And the beautiful part is when you match with someone, the results of the games are posted in the chat and act as an icebreaker, making it so much easier to initiate a fun conversation.”

“Social discovery and gaming is an increasingly interesting intersection, and the team at Smitten have created an amazingly fun experience that truly strikes a chord with young adults,” said Alli Ottarson, Makers' lead on the deal. “Having spent time building a strong relationship with the founders David and Ásgeir, we have been privileged to a front row seat to follow Smitten´s success. We share a common vision for how the next generation will meet and interact, and we’re thrilled to be a part of the Smitten journey."

To learn more about Smitten, please visit smittendating.com.

ABOUT SMITTEN

Smitten is on a mission to make the most fun dating app in the world. Through creative, unique profile games and entertaining content, Smitten transforms how people view online dating. While operating at the intersection of dating, gaming, and entertainment, Smitten gives its users superpowers by making it as easy as swiping to get into a fun and meaningful conversation. Smitten outperforms the industry-leading dating app regarding post-match interactions, with more than 60% of matches progressing to some interaction. Smitten is founded in Iceland by co-founders David Orn Simonarson, CEO, and Asgeir Visir, UX Designer. The seasoned duo has been working together creating social apps to connect people for the past ten years. The team's mission is to create the most fun dating app in the world.

*per research at https://arxiv.org/abs/1607.01952

About Makers Fund

Makers Fund is a global interactive entertainment venture capital firm focused on early-stage investments. Makers is dedicated to furthering growth and innovation in the interactive entertainment industry. With more than 90 portfolio companies to date, Makers provides founders strategic value that is deeply catered to companies across the value chain in the industry. For more information, visit makersfund.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sibel Sunar
fortyseven communications for Smitten
makersfund@fortyseven.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release

Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release

STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye